潮州较好的治疗白癜风汕头治疗白癜风中科就医,普宁最好的看白癜风医生,一个梅州的女孩得了白癜风,潮州卖白癜风药的药店,潮州市白癜风怎么确诊,汕头中科白癜风哪个专家,潮州白癜风要哪治疗好

BEIJING, Oct.25 (Xinhua) -- The China Banking Regulatory Commission (CBRC), the country's top banking regulator, on Tuesday revealed detailed plans to encourage financial support for the country's small and micro-sized enterprises.In a supplementary notice issued to its previous support plan for financing small enterprises, the CBRC said banks should ensure that the growth of loans to small firms will not be slower than that of the average lending, and the growth should be higher than the level of the previous year.Also, commercial banks should give more support to enterprises that borrow less than 5 million yuan (787,401 U.S. dollars), and increase tolerance for non-performing loans to small and micro-sized firms, it said.The regulator has set detailed rules for the establishment of financial institutions serving small businesses, and encouraged banks to create financial instruments to support the development of small high-tech enterprises.The CBRC has also allowed banks to issue special financial bonds to boost financing for small businesses.By the end of August, outstanding loans to small and micro-sized enterprises stood at 14.6 trillion yuan, accounting for 27.2 percent of total lending.

WASHINGTON, Nov. 11 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved HEMACORD, the first licensed hematopoietic progenitor cells-cord cell therapy.HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders affecting the blood forming system. For example, cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic and immune system disorders."The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders," said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.HEMACORD contains hematopoietic progenitor cells (HPCs) from human cord blood. Cord blood is one of three sources of HPCs used in transplants. The other two are bone marrow and peripheral blood. Once these HPCs are infused into patients, the cells migrate to the bone marrow where they divide and mature. When the mature cells move into the bloodstream they can partially or fully restore the number and function of many blood cells, including immune function.

PARIS, Dec. 23 (Xinhua) -- French health authorities on Friday urged 30,000 women to remove the local-made breast implant, pledging that relevant expenses would be covered by the state.The health ministry said in a statement that they spot "no increased risk of cancer currently in women wearing the PIP (Poly Implant Prothese) brand compared with other implants.""However, well-established risks associated with these prostheses are rupture and irritant gel may lead to inflammatory reactions, making it difficult to explant," the statement added.French Health Minister Xavier Bertrand advised French women who have the PIP implants to get them taken out "as a preventive measure but not of an urgent nature." The removal of the implant will be at the state's expense.The recommendation came after eight cases, mainly breast cancer, were reported recently among women with PIP implants.The involved implant was produced by the French company PIP, once the world's third-largest producer of silicone implants who sold its products to tens of thousands of women in more than 65 countries, mainly in South America and western Europe.

WASHINGTON, Oct. 6 (Xinhua) -- The U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) announced Thursday a joint, large-scale, national study of tobacco users to monitor and assess the behavioral and health impacts of new government tobacco regulations.The initiative is the first large-scale NIH/FDA collaboration on tobacco regulatory research since the U.S. Congress granted FDA the authority to regulate tobacco products in an act in 2009. Scientists at NIH's National Institute on Drug Abuse and the FDA's Center for Tobacco Products will coordinate the effort."The launch of this study signals a major milestone in addressing one of the most significant public health burdens of the 21st century," said FDA Commissioner Margaret Hamburg in a statement. "The results will strengthen FDA's ability to fulfill our mission to make tobacco-related death and disease part of America's past and will further guide us in targeting the most effective actions to decrease the huge toll of tobacco use on our nation's health."Investigators will follow more than 40,000 users of tobacco- product and those at risk for tobacco use ages 12 and older. They will examine what makes people susceptible to tobacco use; evaluate use patterns and resulting health problems; study patterns of tobacco cessation and relapse in the era of tobacco regulation; evaluate the effects of regulatory changes on risk perceptions and other tobacco-related attitudes; and assess differences in attitudes, behaviors and key health outcomes in racial-ethnic, gender, and age subgroups."We are pleased to collaborate with the FDA on this study that may provide us with a better understanding of the impact of product regulation on tobacco prevention and cessation," said NIH Director Francis Collins.While smoking rates have dropped significantly since their peak in the 1960s, nearly 70 million Americans ages 12 and older were current users of tobacco products in 2010. As a result, death and disease caused by tobacco use is still a tremendous public health burden. Tobacco use is the leading preventable cause of disease, disability, and death in the United States. Cigarette smoking results in more than 443,000 premature deaths in the United States each year -- more than alcohol, illegal drug use, homicide, suicide, car accidents, and AIDS combined.

SAN FRANCISCO, Jan. 12 (Xinhua) -- Microsoft on Thursday announced a patent licensing agreement with LG Electronics covering the South Korean manufacturer's tablets, smartphones and other consumer devices running Google's Android or Chrome operating system.In a press release, Microsoft said it marks the 11th deal with a device manufacturer leveraging Google's operating system platform, noting that "more than 70 percent of all Android smartphones in the U.S. are now receiving coverage under Microsoft 's patent portfolio."Terms of the deal were not disclosed. So far, Microsoft has struck major cross-licensing patent agreements with HTC, Samsung and Acer, among others.Last September, Microsoft announced a broad patent deal with Samsung. U.S. media reports cited South Korean media as saying that Microsoft had wanted Samsung to pay 10 to 15 U.S. dollars for each Android device.The booming mobile market has been harassed by acrimonious legal battles over patent infringement. Being an open source operating system, Google's Android has become a major target of patent suits.Microsoft has been going after companies that make phones and tablets running Android, rather than directly against Google. But the two tech giants are still engaged in public spats over the issue after Google's top legal officer posted a scathing blog last August accusing Microsoft and other companies of waging "a hostile, organized campaign against Android."Motorola Mobility, which Google announced to acquire in a 12.5 billion-dollar deal last August, currently is the last major Android device vendor that refuses to take a license from Microsoft.Frank Shaw, Microsoft's head of communications, used Twitter to taunt Google on Thursday, twitting "Hey Google -- we are the 70 percent" with a link to their press release.Brad Smith, Microsoft's executive vice president and general counsel, also tweeted "it's time to recognize that in patent world, lawsuits are the 1 percent; license agreements are the 99 percent. "Google so far has made no comments on the Microsoft-LG patent deal.